176 related articles for article (PubMed ID: 38192826)
41. C5aR1 blockade reshapes immunosuppressive tumor microenvironment and synergizes with immune checkpoint blockade therapy in high-grade serous ovarian cancer.
Zhang C; Cao K; Yang M; Wang Y; He M; Lu J; Huang Y; Zhang G; Liu H
Oncoimmunology; 2023; 12(1):2261242. PubMed ID: 37791232
[TBL] [Abstract][Full Text] [Related]
42. mRNAsi-related metabolic risk score model identifies poor prognosis, immunoevasive contexture, and low chemotherapy response in colorectal cancer patients through machine learning.
Weng M; Li T; Zhao J; Guo M; Zhao W; Gu W; Sun C; Yue Y; Zhong Z; Nan K; Liao Q; Sun M; Zhou D; Miao C
Front Immunol; 2022; 13():950782. PubMed ID: 36081499
[TBL] [Abstract][Full Text] [Related]
43. CILP2: A prognostic biomarker associated with immune infiltration in colorectal cancer.
Wang X; Zhang Y; Song N; Li K; Lei S; Wang J; Wang Z; Zhang W
Heliyon; 2023 May; 9(5):e15535. PubMed ID: 37144183
[TBL] [Abstract][Full Text] [Related]
44. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
Cao K; Zhang G; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Oncoimmunology; 2021; 10(1):1969075. PubMed ID: 34527431
[TBL] [Abstract][Full Text] [Related]
45.
Qu S; Liu J; Wang H
Front Immunol; 2021; 12():648416. PubMed ID: 33889156
[TBL] [Abstract][Full Text] [Related]
46. Identification and verification of PTPN3 as a novel biomarker in predicting cancer prognosis, immunity, and immunotherapeutic efficacy.
Zhou Z; Lin Z; Wang M; Wang L; Ji Y; Yang J; Yang Y; Zhu G; Liu T
Eur J Med Res; 2024 Jan; 29(1):12. PubMed ID: 38173048
[TBL] [Abstract][Full Text] [Related]
47. TNNT2 as a potential biomarker for the progression and prognosis of colorectal cancer.
Jing L; Feng L; Zhou Z; Shi S; Deng R; Wang Z; Zhang Y; Ren Z; Liu Y
Oncol Rep; 2020 Aug; 44(2):628-636. PubMed ID: 32627044
[TBL] [Abstract][Full Text] [Related]
48. Comprehensive analysis of transient receptor potential channels-related signature for prognosis, tumor immune microenvironment, and treatment response of colorectal cancer.
Wang L; Chen X; Zhang H; Hong L; Wang J; Shao L; Chen G; Wu J
Front Immunol; 2022; 13():1014834. PubMed ID: 36389750
[TBL] [Abstract][Full Text] [Related]
49. A novel prognostic immunoscore based on The Cancer Genome Atlas to predict overall survival in colorectal cancer patients.
Tang Z; Wu Y; Sun D; Xue X; Qin L
Biosci Rep; 2021 Oct; 41(10):. PubMed ID: 34608935
[TBL] [Abstract][Full Text] [Related]
50. LIMK1: A promising prognostic and immune infiltration indicator in colorectal cancer.
Liu X; Song Q; Wang D; Liu Y; Zhang Z; Fu W
Oncol Lett; 2022 Jul; 24(1):234. PubMed ID: 35720504
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Impact of PD-1 and Tim-3 Expression in Tumor Tissue in Stage I-III Colorectal Cancer.
Kuai W; Xu X; Yan J; Zhao W; Li Y; Wang B; Yuan N; Li Z; Jia Y
Biomed Res Int; 2020; 2020():5294043. PubMed ID: 32509862
[TBL] [Abstract][Full Text] [Related]
52. A subset of patients with MSS/MSI-low-colorectal cancer showed increased CD8(+) TILs together with up-regulated IFN-γ.
Kikuchi T; Mimura K; Okayama H; Nakayama Y; Saito K; Yamada L; Endo E; Sakamoto W; Fujita S; Endo H; Saito M; Momma T; Saze Z; Ohki S; Kono K
Oncol Lett; 2019 Dec; 18(6):5977-5985. PubMed ID: 31788072
[TBL] [Abstract][Full Text] [Related]
53. Integrated Analysis of Expression and Prognostic Values of Acyl-CoA Dehydrogenase short-chain in Colorectal Cancer.
Wu Q; Yan T; Chen Y; Chang J; Jiang Y; Zhu D; Wei Y
Int J Med Sci; 2021; 18(16):3631-3643. PubMed ID: 34790035
[No Abstract] [Full Text] [Related]
54. BICDL1 Predicts Poor Prognosis and is Correlated with Methylation and Immune Infiltration in Colorectal Cancer.
Luo H; Luo J; Ding N; Zhang T; He Y
Pharmgenomics Pers Med; 2023; 16():1109-1126. PubMed ID: 38149287
[TBL] [Abstract][Full Text] [Related]
55. Immune overdrive signature in colorectal tumor subset predicts poor clinical outcome.
Fakih M; Ouyang C; Wang C; Tu TY; Gozo MC; Cho M; Sy M; Longmate JA; Lee PP
J Clin Invest; 2019 Oct; 129(10):4464-4476. PubMed ID: 31524634
[TBL] [Abstract][Full Text] [Related]
56. Immune-related gene-based prognostic index for predicting survival and immunotherapy outcomes in colorectal carcinoma.
Liang Z; Sun R; Tu P; Liang Y; Liang L; Liu F; Bian Y; Yin G; Zhao F; Jiang M; Gu J; Tang D
Front Immunol; 2022; 13():944286. PubMed ID: 36591255
[TBL] [Abstract][Full Text] [Related]
57. Intratumoral TIGIT
Liu Z; Zhou Q; Wang Z; Zhang H; Zeng H; Huang Q; Chen Y; Jiang W; Lin Z; Qu Y; Xiong Y; Bai Q; Xia Y; Wang Y; Liu L; Zhu Y; Xu L; Dai B; Guo J; Wang J; Chang Y; Zhang W
J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32817209
[TBL] [Abstract][Full Text] [Related]
58.
Chen Z; Chen Q; Li S; Tu S; Chen Q; Wang A
Ann Transl Med; 2022 Feb; 10(3):144. PubMed ID: 35284546
[TBL] [Abstract][Full Text] [Related]
59. Poor clinical outcomes and immunoevasive contexture in interleukin-9 abundant muscle-invasive bladder cancer.
Zhou Q; Zhang H; Wang Z; Zeng H; Liu Z; Huang Q; Lin Z; Qu Y; Xiong Y; Wang J; Chang Y; Bai Q; Xia Y; Wang Y; Liu L; Dai B; Guo J; Zhu Y; Xu L; Xu J
Int J Cancer; 2020 Dec; 147(12):3539-3549. PubMed ID: 32734613
[TBL] [Abstract][Full Text] [Related]
60. High expression of
Li N; Zhou Z; Zhang L; Tang H; Chen X; Zhou H
Transl Cancer Res; 2022 May; 11(5):981-992. PubMed ID: 35706814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
